PURPOSE: To investigate the clinical and anti-inflammatory effects of omalizumab in patients with severe asthma.
METHODS: Nine patients treated with omalizumab were enrolled in this study, and were assessed to identify reactive oxidative metabolites (ROM) in their serum and exhaled nitric oxide (FeNO). The clinical profiles, respiratory function test and asthma control test (ACT) results were also evaluated.
RESULTS: The levels of FeNO 1 month after treatment with omalizumab decreased in 57% (4/7) of the patients, and 4 months after treatment in 75% (3/4) of patients, compared to the levels before treatment. The levels of ROM also decreased at 1 month and 4 months after treatment with omlizumab, in 44% (4/9) and 83% (5/6) of patients, respectively. The %PEF was significantly increased 4 months after treatment with omalizumab compared to that before treatment (88.2±30.8% vs 69.7±24.2% ; p<0.05). In 33% (3/9) of patients, the FEV1 increased more than 200 ml by 1 month after treatment with omalizumab, compared to that before treatment. The ACT score also significantly increased at 1 month and 4 months after treatment compared to that recorded at pretreatment (20.7±2.8, 21.5±1.9 and 14.6±4.1, respectively)
CONCLUSIONS: The anti-inflammatory effects of omalizumab may therefore help to improve the clinical findings in patients with severe asthma.
CLINICAL IMPLICATIONS: Omalizumab therapy has beneficial and add-on effects for patients with inadequately controlled severe asthma.
DISCLOSURE: The following authors have nothing to disclose: Ryo Shirai, Atsuko Iwata, Hisako Sonoda, Daisuke Yoshioka, Kazuhiko Hashinaga, Hiroshi Ishii, Kenji Kishi, Issei Tokimatsu, Eiji Yamagata, Kazufumi Hiramatsu, Jun-ichi Kadota
No Product/Research Disclosure Information